Antibodies, boosters and optimizing SARS-CoV-2 vaccine for transplantation: A call for more research

Abstract

Despite emerging data suggesting reduced antibody responses among SOT recipients following SARS-CoV-2 vaccine, critical unanswered questions remain. The clinical implications of the reduced humoral response need to be assessed through prospective studies. Studies are likewise needed to inform which vaccine dosing strategies result in improved immunity and if such approaches maximize protection against severe infection in the vulnerable transplant population.